| P50 | author | Mark A Fiala | Q60370573 |
| P2093 | author name string | Shireen Vali | |
| | Taher Abbasi | |
| | Abdel Kareem Azab | |
| | Feda Azab | |
| | Ravi Vij | |
| | Barbara Muz | |
| | Pilar de la Puente | |
| | Joseph Abraham | |
| | Anuj Tyagi | |
| | Zeba Sultana | |
| | Nicholas Potter | |
| | Jacob Paasch | |
| P2860 | cites work | PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? | Q24296651 |
| | Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation | Q27684731 |
| | High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 |
| | FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation | Q28236353 |
| | New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway | Q29616144 |
| | Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement | Q30160287 |
| | CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. | Q30487339 |
| | RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. | Q30488936 |
| | Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib | Q34013386 |
| | PI3K/p110{delta} is a novel therapeutic target in multiple myeloma | Q34124937 |
| | Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. | Q34184917 |
| | An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib | Q34291281 |
| | Multiple myeloma. | Q34362643 |
| | Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone | Q34420112 |
| | The molecular classification of multiple myeloma | Q34530992 |
| | Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 |
| | Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. | Q35564293 |
| | Targeting the PI3K-Akt pathway in human cancer: rationale and promise | Q35571372 |
| | P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment | Q35776423 |
| | Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. | Q36155317 |
| | Bone marrow microenvironment and the identification of new targets for myeloma therapy | Q36162703 |
| | Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo | Q36697045 |
| | Emerging drugs in multiple myeloma | Q36758600 |
| | The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells | Q36815262 |
| | Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. | Q36986301 |
| | Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors | Q37187543 |
| | Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. | Q37250634 |
| | Latest advances and current challenges in the treatment of multiple myeloma | Q37986287 |
| | Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives | Q38021160 |
| | Carfilzomib | Q38080038 |
| | Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 |
| | The AKT kinase is activated in multiple myeloma tumor cells | Q38459102 |
| | Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations | Q39338784 |
| | Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition | Q39502963 |
| | Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice | Q39564473 |
| | Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. | Q39585342 |
| | Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival | Q39621100 |
| | Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. | Q39718152 |
| | Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line | Q39811914 |
| | Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 |
| | Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. | Q39833233 |
| | The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. | Q39986126 |
| | Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells | Q40328451 |
| | Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma | Q43761443 |
| | Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications | Q44098361 |
| | Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms | Q44452179 |
| | Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway | Q44588841 |
| | Oncogenic signaling of class I PI3K isoforms | Q46902768 |
| | Multiple Myeloma | Q56453538 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 89-101 | |
| P577 | publication date | 2014-01-09 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance | |
| P478 | volume | 165 | |